Impact of Splenectomy on Thrombocytopenia, Chemotherapy, and Survival in Patients with Unresectable Pancreatic Cancer

Department of Surgery, Division of General Surgery, David Geffen School of Medicine at University of California Los Angeles, 10833 Le Conte Avenue, CHS, Room 72-215, Los Angeles, CA 90095-6904, USA.
Journal of Gastrointestinal Surgery (Impact Factor: 2.8). 03/2010; 14(6):1012-8. DOI: 10.1007/s11605-010-1187-x
Source: PubMed


Patients with unresectable pancreatic cancer (PDAC) or endocrine tumors (PET) often develop splenic vein thrombosis, hypersplenism, and thrombocytopenia which limits the administration of chemotherapy.
From 2001 to 2009, 15 patients with recurrent or unresectable PDAC or PET underwent splenectomy for hypersplenism and thrombocytopenia. The clinical variables of this group of patients were analyzed. The overall survival of patients with PDAC was compared to historical controls.
Of the 15 total patients, 13 (87%) had PDAC and 2 (13%) had PET. All tumors were either locally advanced (n = 6, 40%) or metastatic (n = 9, 60%). The platelet counts significantly increased after splenectomy (p < 0.01). All patients were able to resume chemotherapy within a median of 11.5 days (range 6-27). The patients with PDAC had a median survival of 20 months (range 4-67) from the time of diagnosis and 10.6 months (range 0.6-39.8) from the time of splenectomy.
Splenectomy for patients with unresectable PDAC or PET who developed hypersplenism and thrombocytopenia that limited the administration of chemotherapy, significantly increased platelet counts, and led to resumption of treatment in all patients. Patients with PDAC had better disease-specific survival as compared to historical controls.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Abdominal surgery in gastric carcinoma patients with concurrent portal hypertension (PHT) is highly risky due to liver function impairment. This study aimed to identify the optimal surgical modalities for the concomitant conditions Thirty patients with gastric adenocarcinoma and concurrent PHT who received radical (n=28) or palliative (n=2) gastrectomy plus D0/D1 (n=12) or D2 (n=18) lymphadenectomy, were reviewed. Logistic and Cox regression analysis were used to determine the correlation of predefined perioperative factors with surgical morbidity and overall survival (OS), respectively. Sixteen (53.3%) patients experienced postoperative complications; the rates were 26.7% (4/15), 72.7% (8/11) and 100.0% (4/4) in patients with Child-Pugh classification (CPC) Class A, B and C, respectively. Five (16.7%) patients did not survive due to pulmonary embolism (n=1), anastomotic leakage (n=2), and multiple organ dysfunction syndrome (n=2). The median survival time was 15.0 months. TNM staging (p=0.027), CPC (p=0.048) and preoperative ascites (p=0.001) were significantly associated with OS as determined in the multivariate analysis. Concomitant surgical treatment of PHT depends on the presence of hypersplenism and variceal bleeding risk. Baseline CPC, tumor TNM staging and the preoperative ascites predict the risks of surgical complications and long-term outcome.
    No preview · Article · Jul 2011 · Hepato-gastroenterology
  • [Show abstract] [Hide abstract]
    ABSTRACT: The aim of this study is to investigate the efficacy and safety of extracorporeal high-intensity focused ultrasound (HIFU) in treatment of hypersplenism. Fifteen adult dogs, weighing 13-18 kg were divided into three groups: sham group, SVL group undergoing splenic vein ligation (SVL) after laparotomy, and SVL + HIFU group receiving SVL followed by extracorporeal HIFU. Pathologic and hematologic analyses were performed. We also reviewed the clinical data of 19 patients with secondary hypersplenism caused by liver cirrhosis or hepatocellular carcinoma who underwent extracorporeal HIFU. Extracorporeal HIFU significantly diminished the volume of the spleen of animals, coupled with occurrence of coagulation necrosis and fibrosis in the target area. Both platelet and red blood cell counts were significantly restored by HIFU intervention. Similarly, HIFU treatment improved the hematologic parameters in patients with hypersplenism, and no major complications were encountered. Extracorporeal HIFU intervention is effective and safe in managing secondary hypersplenism.
    No preview · Article · Sep 2012 · Ultrasound in medicine & biology

  • No preview · Article · Mar 2013 · The American surgeon
Show more